Overview of Roseol

Roseol is a prescription pharmaceutical preparation whose core active substance is Loxoprofen, classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its fundamental therapeutic purpose is to provide symptomatic relief by moderating the body's response to pain, inflammation, and fever. The medicine belongs to the specific chemical family of propionic acid derivatives.

Quick Facts

Property	Description
Active Ingredient	Loxoprofen (Loxoprofen sodium hydrate)
Form	Primarily Oral Tablets
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin	Synthetic
Functional Type	Prodrug

What Type of Medicine is Roseol? (Definition and Classification)

Roseol is categorized as an NSAID, sharing its central mechanism with other widely used substances in this class. This classification signifies that the drug's action is rooted in a molecular process that targets inflammatory pathways. The preparation is a single-ingredient product, containing only the active substance Loxoprofen.

The Loxoprofen active ingredient is primarily supplied for oral administration in the form of tablets, though its compound is also formulated into transdermal patches for topical application in certain global markets. Loxoprofen has a dual function in managing both pain and inflammation. Roseol is a recognized agent for the temporary management of symptoms associated with acute inflammatory conditions.

Loxoprofen: A Synthetic Prodrug Composition (Composition and Origin)

The active ingredient, Loxoprofen, is a synthetic small-molecule substance that possesses the unique functional characteristic of being a prodrug. A prodrug is an administered compound that must undergo a necessary biotransformation in vivo to yield its therapeutically active structure, known as the trans-alcohol metabolite.

Loxoprofen is rapidly absorbed, followed by swift enzymatic activation. The oral formulation of Roseol is typically a prescription-only (Rx) medicine, distinguishing its distribution from some over-the-counter (OTC) NSAIDs available globally. The tablet contains Loxoprofen sodium hydrate alongside standard pharmaceutical excipients—inert components necessary to form the solid oral dosage.

What is the General Therapeutic Purpose of Roseol? (Mechanism and Benefit)

Roseol's general therapeutic purpose is the alleviation of acute discomfort, achieved through its key effects of analgesia (pain relief), anti-inflammation, and antipyresis (fever reduction). These effects stem from the active metabolite's capacity to inhibit cyclooxygenase (COX) enzymes.

A typical use scenario involves the short-term relief of musculoskeletal discomfort. By limiting the activity of these enzymes, Roseol significantly reduces the biosynthesis of prostaglandins, which are the biological mediators that drive pain signal transmission, localized swelling, and the elevation of body temperature.

What side effects are possible with Roseol?

Possible side effects and safety information

The safety profile for Roseol (Loxoprofen), an NSAID, is established through comprehensive clinical and post-marketing surveillance documented by government health authorities. Official regulatory documents classify potential adverse reactions primarily by frequency and the body system affected, ensuring clarity on the medicine's risk profile.

Adverse events are often grouped into System-Organ-Classes (SOC), which commonly include Gastrointestinal Disorders (e.g., stomach discomfort, nausea, vomiting) and Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus). These effects are among the most frequently reported adverse reactions listed in official labeling. Infrequently reported effects involve systems such as the nervous system, including drowsiness and headache.

Regulatory safety information also highlights Serious Adverse Reactions that are rare but clinically significant, requiring careful consideration. These officially documented serious events include manifestations of Shock/Anaphylaxis, severe conditions affecting the Blood and Lymphatic System Disorders (such as Agranulocytosis), Serious Renal Disorders (such as acute renal failure), and severe reactions of the skin (e.g., Stevens-Johnson Syndrome).

Population-Specific Safety Statements are defined in the labeling. Use requires caution and monitoring in older adults, who may have increased susceptibility to adverse effects. The medicine is restricted or not recommended during the late stages of pregnancy due to documented risks to the fetus. Furthermore, official contraindications specify that the medicine must not be used by individuals with certain high-risk conditions, including a history of active peptic ulcers, severe hepatic function disorders, or severe cardiac failure.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Loxoprofen, the active ingredient in Roseol, requires seeking immediate medical attention. Regulatory documents for this Nonsteroidal Anti-inflammatory Drug (NSAID) often note that specific data detailing Loxoprofen overdose manifestations is limited or unavailable in the product labeling. Overdose presentations are generally consistent with the known toxicity profile of the NSAID drug class.

Documented Manifestations	Required Emergency Actions
Potential for acute renal failure	Seek immediate medical attention
Gastrointestinal symptoms (e.g., nausea, vomiting)	Hospital monitoring is required
Central nervous system disturbances	No specific antidote is known

Documented severe outcomes include the risk of acute renal failure and disturbances to the central nervous system, which may involve disorders of consciousness or excessive drowsiness. Gastrointestinal symptoms, such as nausea and epigastric pain, are also possible. No specific antidote is known to counteract Loxoprofen toxicity. Therefore, management is mandated to be symptomatic and supportive treatment. Medical professionals may consider the administration of activated charcoal or gastric lavage if the overdose ingestion was recent. Close hospital monitoring is required for continuous assessment of renal, hepatic, and neurological status due to the potential for serious, delayed systemic toxicity. Immediate medical help must be sought for any suspected overdose situation.

Therapeutic Uses of Roseol

Roseol (Loxoprofen) is commonly used to provide symptomatic relief across several key areas where symptoms that interfere with daily functioning create noticeable physiological strain and tension.

Relief for Pain and Inflammation in Musculoskeletal Conditions

Roseol is generally applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort such as osteoarthritis, rheumatoid arthritis, lumbago (lower back pain), and periarthritis of the shoulder. It contributes to easing the overall symptom load by managing the symptoms related to physical discomfort, stiffness, and swelling that interfere with daily functioning.

Management of Acute Pain and Febrile Symptoms

The medication is also used in situations involving certain distressing symptoms, such as pain related to dental procedures, neuralgia, forms of headache, and the symptoms of painful menstruation (dysmenorrhea). It is applied in scenarios where additional management of discomfort is required in contexts involving acute or disruptive episodes, such as pain and inflammation following trauma or procedures. Furthermore, it may be part of symptomatic management in situations where patients experience fever.

Quick Fact: Symptomatic Support
Primary Actions	Helps with pain relief, reducing inflammation, and lowering fever.
Target Conditions	Chronic joint disorders and acute symptomatic episodes.
Key Benefit	Contributes to easing the overall symptom load during periods of distress.

Regulatory References

official summary from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Eligibility and Restrictions for Use

Roseol (Loxoprofen) is permitted for use by adults, typically those 15 years of age and older. Its use is strictly defined by regulatory guidelines that prohibit the medicine for several key populations.

Roseol is contraindicated in patients diagnosed with active peptic ulcers or a history of recurrent ulcers, as well as those with severe cardiac, renal, or hepatic function failure. Absolute prohibition also applies to individuals with a history of aspirin-induced asthma or known hypersensitivity to any ingredient in the preparation. Women in the late stages of pregnancy are strictly prohibited from using this medicine.

Regulatory rules specify that pediatric populations (under 15 years) should not use the medicine, as its safety profile is not established in these groups. Use is restricted during early/mid-pregnancy, and nursing mothers are advised to discontinue breastfeeding if the drug is deemed essential. Caution is mandatory for elderly subjects and for patients with pre-existing conditions such as non-severe organ dysfunction, bronchial asthma, or inflammatory bowel diseases like ulcerative colitis or Crohn's disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Roseol (Loxoprofen) has specific interaction patterns that are formally documented by regulatory agencies, categorized into prohibited combinations, exposure modifications, and pharmacodynamic risk amplifications. These patterns establish constraints for co-administration.

Contraindicated Combinations: Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including common analgesic doses of Aspirin, is officially prohibited due to a substantially increased risk of adverse effects. Combinations with second-generation Quinolone Antibiotics (e.g., Ciprofloxacin) are also listed as contraindicated, as this pairing carries a documented risk of inducing seizures.

Exposure and Risk Alterations: Loxoprofen may significantly increase the plasma concentrations of certain narrow-therapeutic-index substances, such as Lithium Salts, Methotrexate, and Cardiac Glycosides (e.g., Digoxin), resulting from reduced renal clearance. The drug may also reduce the therapeutic effectiveness of Diuretics and ACE Inhibitors. Co-administration with Anticoagulants, Antiplatelet drugs, and SSRIs is officially documented to enhance the risk of bleeding or hemorrhage. Interactions with CYP3A Modulators are noted to alter the Loxoprofen active metabolite concentration. The official profile restricts co-consumption of Alcohol due to the enhanced risk of gastrointestinal bleeding. Additionally, administration must be separated from Mifepristone to prevent a reduction of its efficacy.

Mechanism of Action

Mechanism of Action: How Roseol Works

Roseol's primary action is exerted through the inhibition of the Viral DNA Polymerase of Human Herpesvirus 6 (HHV-6) and HHV-7. It functions as a nucleoside analog, which, upon incorporation into the growing viral DNA chain, disrupts the synthesis of new viral genetic material. This molecular interference prevents the virus from completing its reproductive cycle, resulting in decreased production of new viral progeny and a lower systemic viral titer.

By suppressing viral replication, the reduction of viral activity attenuates the stimulus for the release of pyrogenic cytokines and inflammatory mediators by host immune cells. This modulation of the acute systemic inflammatory cascade is a key physiological consequence, modulating thermoregulatory signals through the suppression of pro-inflammatory mediators. The mechanism is selectively engaged during the active lytic (replicative) phase of the infection, influencing the balance of physiological responses and dictating the rate of viral clearance in the affected pathways.

Dosage and Administration Information

Roseol, whose active substance is Loxoprofen, is administered via two primary routes: the 60 mg oral tablet for systemic use and the 100 mg topical patch for localized application. The overall usage pattern is determined by specific dosing regimens and contextual constraints.

Administration and Dosing Regimens

Use Pattern	Single Adult Dose	Frequency	Contextual Rule
Scheduled Oral Use	60 mg of Loxoprofen sodium	Three times daily (TID)	Avoid taking on an empty stomach
Acute Oral Use (PRN)	60 mg per dose	Up to two times daily (Max 180 mg/day)	Taken only with or after meals
Topical Use	One 100 mg patch	Once daily	Apply only to non-damaged skin

The oral form of Loxoprofen must always be consumed with or after a meal to adhere to administration constraints, with consumption under fasting conditions strictly avoided. Administration of the oral form is not authorized for individuals under 15 years of age. For scheduled long-term administration, close monitoring and laboratory examinations may be necessary, particularly in older adults. If a scheduled dose is missed, the standard procedure is to skip the dose if the next one is due soon, and never take two doses at one time.

Recent Clinical Evidence

Research evidence / Overview of Studies for Roseol

Evidence for Symptomatic Relief in Musculoskeletal Conditions

Roseol (Loxoprofen) has been studied in research examining measured changes in symptoms of chronic joint disorders. For osteoarthritis (OA), research has explored how symptoms change over time, specifically focusing on whether there was a measured change in pain and associated functional imbalance. The available evidence includes short-term randomized controlled trials (RCTs) where Loxoprofen was evaluated against active comparators and against its own topical patch formulation. These studies monitored patient-reported outcomes describing perceived discomfort, using validated tools to measure pain intensity and outcomes reflecting daily functioning or activity level.

Studies typically reported patterns observed in the measured symptomatic outcomes across the short follow-up periods, including the recorded measurements of pain levels and function scores in the evaluated populations. However, long-term effects are not fully established by these initial controlled trials, as the follow-up durations were limited, often lasting only two to four weeks. Additionally, the results apply primarily to the specific populations studied, which were largely adults from certain regions, meaning data for other diverse groups remains limited.

Evidence for Acute Pain Episodes, Trauma, and Low Back Pain

Research has explored Loxoprofen's application in conditions associated with acute or disruptive episodes, such as acute traumatic injuries (like sprains and contusions) and short-term low back pain (LBP). These were often short-term RCTs used in research contexts involving fluctuating or unstable symptoms. Many studies evaluated its symptomatic focus against an active comparator formulation. For LBP, trials often compared Loxoprofen with other active comparators and monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies over the defined time intervals. However, the LBP evidence examines outcomes related to temporary physiological imbalance and does not provide evidence for long-term management strategies for chronic back conditions. Comparative evidence against a broad range of active comparators is limited, as the trials often focused on specific regional comparators.

Duration of Evidence: Long-Term Studies and Follow-up

Research exploring short-term symptom changes, particularly in RCTs, has predominantly involved follow-up durations of two to four weeks. The evidence base is defined by studies examining short-term measurements when used in studies conducted during periods of increased symptom activity. However, the long-term effects are not fully established through controlled clinical trials. Extended data collection is largely derived from post-marketing surveillance (PMS), which contributes to the understanding of general use patterns but does not offer the same level of certainty as head-to-head RCTs regarding sustained outcomes or durability of response over many months.

Evidence in Specific Patient Populations

Most research has concentrated on the general adult population. For older adults with conditions such as lumbar pain, some observational studies have been conducted. Research has also been conducted for other specific inflammatory conditions, such as Ankylosing Spondylitis (AS). Because these AS studies had modest sample sizes and focused primarily on comparing formulations rather than efficacy against placebo, the data for certain groups remain insufficient, and research provides limited insight into long-term outcomes for these specific populations.

What the Research Landscape Shows About Consistency and Gaps

The research base for Roseol describes a short-term symptomatic focus, with studies exploring its use in conditions characterized by fluctuating or episodic manifestations. Evidence quality varies across studies, with some indications supported by controlled trials and others relying more heavily on observational or older clinical data. A key limitation is the geographic concentration of the evidence, as a significant portion of the data originates from specific regional research settings. The evidence highlights what is known for short-term outcomes but shows that long-term effects are not fully established.

Key Studies & References

A post marketing survey on the side-effects of loxoprofen

Frequently Asked Questions (FAQ)

Common questions about Roseol (FAQ)

Q: How quickly do people generally notice the effects of Roseol?

Studies on Roseol's active ingredient, Loxoprofen, indicate that it is rapidly absorbed following administration. Once converted into its active form, the metabolite reaches its highest concentration in the bloodstream within 30 to 50 minutes, according to scientific literature.

Q: What are the most common things people misunderstand about Roseol?

Official information describes Roseol as an NSAID (Nonsteroidal Anti-inflammatory Drug) prodrug intended primarily for short-term symptomatic relief. A key regulatory constraint is that the medicine must always be taken with or after meals, as taking it on an empty stomach is formally avoided according to regulatory administration constraints.

Q: Can Roseol cause stomach upset or digestive issues?

Yes. According to official safety labeling, Gastrointestinal Disorders are listed among the most frequently reported adverse reactions. These effects can include stomach discomfort, nausea, or vomiting.

Q: Is it possible to have an allergic reaction to Roseol?

Yes, it is possible. Official safety documents list Shock/Anaphylaxis as a serious adverse reaction that has been documented. Furthermore, a history of known hypersensitivity (severe allergic reaction) to any ingredient in the preparation is listed as an official contraindication for use.

Q: What happens if a dose of Roseol is missed?

Regulatory procedure for oral administration instructs that if the next scheduled dose is due soon, the missed dose should be skipped. Regulatory procedure states that two doses must never be taken simultaneously.

Q: Can children or adolescents use Roseol?

Regulatory rules specify that the medicine is not authorized for use by individuals under 15 years of age. Its use is defined for adults, which includes adolescents 15 years and older, according to official dosing regimens.

Q: How long after stopping Roseol can I start taking another medication that might interact?

Scientific literature indicates that the active metabolite of Loxoprofen has an elimination half-life of approximately 15 hours. The full time required for complete clearance of the medicine from the body can vary, and regulatory agencies document this duration to inform the safe time separation from interacting drugs.

Q: How long does Roseol stay in the body after stopping use?

The active metabolite of Loxoprofen has an elimination half-life documented in scientific literature as approximately 15 hours. The drug is largely eliminated from the body through renal excretion.

Q: Is Roseol the same as [other common drug name]?

Roseol's active ingredient, Loxoprofen, is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is a propionic acid derivative. This places it in the same pharmacological class as certain other common pain relievers, but it is a distinct chemical entity.

Q: Is it common for people to feel tired when starting Roseol?

Official safety labeling lists drowsiness as an infrequently reported effect related to the Nervous System Organ Class. This effect is not described as one of the most common or frequent side effects in the official documentation.

Q: What are the main findings from the clinical trials of Roseol?

Clinical trials have described measured changes in symptoms for conditions such as osteoarthritis and acute pain episodes. Researchers monitored patient-reported outcomes to measure changes in pain intensity and associated daily functioning.

Q: Is Roseol considered a high-risk medication during pregnancy (purely informational/classification)?

Official labeling states that the medicine is strictly prohibited during the late stages of pregnancy due to documented risks to the fetus. Its use is also restricted during early and mid-pregnancy.

Q: Does Roseol contain any common allergens like gluten or lactose?

The oral formulation contains the active ingredient alongside standard pharmaceutical excipients (inert components). The specific list of excipients, which may contain common allergens, is detailed in the official prescribing information for the specific product.

Q: Can Roseol interfere with driving or operating machinery?

Since the safety profile lists infrequently reported effects such as drowsiness and dizziness, official labeling includes safety statements regarding potential interference with tasks requiring full mental alertness, such as driving or operating heavy machinery.

Q: Is Roseol known to be habit-forming?

Roseol is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not typically categorized as a controlled substance with known potential for abuse or habit formation.

Q: Are there specific instructions for what to do if a side effect occurs (non-directive)?

Official safety information requires careful consideration for adverse reactions. In the event of officially documented serious events, such as manifestations of Shock/Anaphylaxis, the information notes that immediate medical intervention is required for these documented serious events.

Q: How does the mechanism described in 'How Roseol works' relate to its main use?

The mechanism of inhibiting cyclooxygenase (COX) enzymes directly relates to its therapeutic purpose. This action significantly reduces the biosynthesis of prostaglandins, which are the biological mediators that drive pain signal transmission, localized swelling, and fever.

Q: Are there any specific lab tests required before or during treatment with Roseol?

Regulatory guidelines state that close monitoring and laboratory examinations may be necessary for scheduled long-term administration. This is particularly relevant for older adults due to their potentially increased susceptibility to adverse effects.

Q: Does Roseol have any common interactions with herbal remedies?

The official interaction profile lists specific drug-drug combinations and restrictions on co-consumption of certain substances. However, specific interactions with most herbal remedies are not explicitly detailed in the core regulatory documents.

Q: What is the typical timeframe for a course of Roseol treatment?

The controlled clinical evidence base largely involves studies and trials with short follow-up durations, often lasting two to four weeks. These studies are designed to examine short-term symptomatic outcomes and inform typical treatment periods.

Q: Is it normal to feel a mild headache when first starting Roseol?

Official safety labeling lists headache as an infrequently reported effect related to the Nervous System Organ Class. It is not listed as one of the most frequent or common side effects.

Q: Are there any specific physical symptoms that require immediate medical attention while taking Roseol?

Yes. Officially documented serious events such as manifestations of Shock/Anaphylaxis, severe skin reactions (e.g., Stevens-Johnson Syndrome), or signs of severe renal or hepatic disorders are listed as conditions that require immediate medical attention.

How should Roseol be stored and disposed of?

How to Store and Dispose of Roseol (Loxoprofen)

Storage Requirements

Roseol (Loxoprofen) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in a tightly closed container to protect it from moisture and excess heat. The regulatory label allows for brief temperature excursions between 15 C and 30 C. To maintain integrity, the medicine must not be stored in a bathroom and should be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Roseol should be disposed of safely, ideally using an official drug take-back program. If a take-back program is unavailable, the medicine may be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being placed in the trash. The tablets must not be flushed down the toilet or poured down a sink.

Roseol